case study : prodigy health supplier Prodigy is a nationwide specialty distributor of urgently-needed pharmaceutical drugs, used primarily for treating snake-bite victims, and he- mophiliac trauma patients. The network of redundant distribution hubs managed by Prodigy are accredit- ed by the National Board of Pharmacy as a Verified- Accredited Wholesale Distributors (VAWD). The market for hemophilia recombinant therapies is set to grow from $5.4 billion in 2014 to $6.3 billion by 2024, according to research and consulting firm GlobalData. 1 Drivers of hemophilia A and B recombinant therapies include the disease’s growing prevalence and the increasing use of recombinant products and prophylactic regimens. 2 The medicines that Prodigy distributes are characterized by the

Join for free to read